Dec 15 (Reuters) – The U.S. Food and Drug Administration has approved Daiichi Sankyo’s therapy in combination with Roche’s drug for the first-line treatment of patients with a type of breast cancer, the regulator said on Monday.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Alan Barona)
